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1. Introduction 
There is growing interest in the use of nutraceutical products which includes probiotics, 
prebiotics and related metabolites with cholesterol-lowering properties to prevent 
cardiovascular diseases (CVDs) [1]. Probiotics are beneficial bacteria that influence the 
health of the host by improving their microbial balance. Modifications of intestinal flora 
have been shown to be beneficial on lipid metabolism in mice [2-6], rats [7-11], guinea pigs 
[12] and pigs [13]. In contrast, studies in humans [14,15] indicated that the role of fermented 
milk products as hypocholesterolaemic agents were inconsistent but more reliable effects 
were documented in the recent clinical studies [16-19]. The cholesterol-lowering effect of 
probiotics was found to be highly strain-specific as different strains exhibited different 
levels of cholesterol-lowering activity [20-22]. Therefore, it is important to identify probiotic 
strains that exhibit excellent cholesterol-lowering ability.  
Cholesterol-reducing mechanism(s) by probiotics remain to be elucidated. Deconjugation of 
bile salt by the bile salt hydrolase (BSH) enzyme and subsequent co-precipitation of 
cholesterol at acidic pH is one of the models frequently used to explain 
hypocholesterolaemic effects of probiotics [21,23]. Other studies have shown reduction of 
cholesterol through assimilation of cholesterol into bacterial cell membrane [24-28], 
adhesion of cholesterol onto bacterial cell surface [28] and through the binding of bile acids 
to bacterial exocellular polysaccharides [29]. A recent study showed the ability of probiotics 
to be able to produce protein(s) with cholesterol-lowering effect [30]. Probiotics are able to 
grow in prebiotics (indigestible carbohydrate) producing short chain fatty acids (SCFAs). 
Butyrate, a SCFA has the ability to inhibit liver cholesterol synthesis [31]. The role of 
probiotics as hypocholesterolaemic agents should be further explored.  
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2. Cardiovascular disease and treatments 
Hypercholesterolemia is the major cause of coronary diseases. Diseases related to 
hypercholesterolemia have been projected to be the number one leading cause of death in 
the world by 2020 [32]. In fact, Roth et al. [33] concluded that the global burden of CVDs 
requires immediate action based on analysis of health examination survey of eight countries. 
An ideal strategy to control this disease is to lower cholesterol through a combination of 
lifestyle and pharmacologic approaches.  
Cholesterol-lowering drugs that are available have different mechanisms of actions. Statins 
(3-hyroxy-3-methylglutaryl coenzyme A reductase inhibitors) are generally able to inhibit 
cholesterol synthesis in the liver and peripheral tissues. They have been extensively studied 
and found to possess better therapeutic effects than other lipid lowering drugs [34]. A recent 
meta-analysis that involved 14 studies with over 90000 patients for 5 years showed that 
statins reduced the risks of major cardiovascular events and overall mortality [35]. Yet, 
another meta-analysis of 11 studies showed no reduction in mortality with the use of statins 
[36]. A similar conclusion was observed in the recent Cochrane review [37]. However, Blaha 
et al. [38] emphasize that statins are critical in patients with increased cardiovascular risk as 
opposed to low-risk patients. This is probably due to the adverse effects related to the use of 
this class of drugs, which include myopathy [39] and cognitive impairment [40-42]. Other 
pharmacological agents that are used in the management of hypercholesterolemia are bile 
acid sequestrants, cholesterol absorption inhibitors, niacin, and fibrates. Nevertheless, these 
drugs have also been associated with many adverse effects that limit treatment compliance 
as well as quality of life.  
Non-pharmacological treatment serves as a supportive therapy to reduce cardiovascular 
risk in otherwise healthy people. The common recommendations are dietary modifications, 
exercise and weight control. Modification of diet will allow lower drug doses that will 
reduce the adverse effects of drugs. Clifton et al. [43] reported that although dietary 
intervention to lower cholesterol had been effective it was underutilized. The idea of 
preventing and lowering hypercholesterolemia using ‘functional foods’ has emerged 
recently. Functional foods are broadly defined as foods that provide additional 
physiological benefits to the consumer beyond basic nutrition [44]. Functional foods that are 
commercially available with health claims of reducing cholesterol levels include oat bran 
fibre, soy protein, fish oil fatty acids, plant sterols and stanols, probiotics and prebiotics [44].  
3. Definitions of probiotics 
Over the years, probiotics have been defined in several ways. The term probiotic was coined 
by Lily and Stillwell [45] to describe growth-promoting factors produced by 
microorganisms. Parker [46] subsequently defined it as organisms and substances, which 
contribute to intestinal microbial balance. However, Fuller [47] pointed out that this 
definition was too broad and redefined probiotic as a live microbial feed supplement, which 
beneficially affects the health of the host animal by improving its intestinal microbial 
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balance. Havenaar et al. [48] considered the definition given by Fuller [47] to be restricted to 
feed supplements, animals and the intestinal tract, and described probiotics as mono or 
mixed cultures of live microorganisms which, when applied to animal or human, 
beneficially affected the host by improving the properties of the indigenous microflora. This 
definition does not restrict probiotic activities to intestinal microflora only, but also includes 
microbial communities at other sites of the body; the probiotic may consist of more than one 
bacterial species and that it can be applied to both human and animal. Salminen et al. [49] 
defined probiotics as microbial cell preparations or components of microbial cells that have 
a beneficial effect on the health and well-being of the host. This definition implies that 
probiotics do not necessarily need to be viable, and are limited to human only. Finally, 
FAO/WHO [50] described probiotics as live microorganisms which when administered in 
adequate amount confer a health benefit on the host.  
4. Characteristics and health benefits of probiotics 
Evidence is emerging that the intestinal flora does not exist as an entity by itself, but is 
constantly interacting with the environment, the central nervous system, the endocrine and 
the immune system [51-54]. There is growing scientific evidence to support the concept that 
maintenance of gut microflora may prevent or treat intestinal disorders [55-57]. Therefore, 
attempts have been made to improve health status by modulating the indigenous intestinal 
microbiota through probiotics [58,59]. However, for probiotics to be effective the selection of 
strains must be based on criteria that are coherent with the claim the probiotic is used for. 
Rational selection and validation of promising microbial strains should be based on 
scientific evidence obtained from in vitro models followed by in vivo studies. The important 
criteria that have been put forward by FAO/WHO [60] in the selection of food probiotics 
include identification of strains using state-of-the-art techniques, ability to tolerate gastric 
juice and bile, maintain stability and most importantly prove to be safe and beneficial to the 
consumer. The most common microorganisms in probiotic preparations that possess health 
benefits are lactic acid bacteria (LAB), mainly lactobacilli and bifidobacteria. Probiotics have 
been reported to improve intestinal tract health, enhance the immune system, reduce 
symptoms of lactose intolerance, decrease the prevalence of allergy, treat colitis and lower 
serum cholesterol levels [61-63].  
5. Hypocholesterolaemic effects of probiotics 
There has been considerable interest in the beneficial effects of lactobacilli and bifidobacteria 
on lipid metabolism since the discovery that fermented milk containing a wild Lactobacillus 
strain has hypocholesterolaemic effect in humans [64]. This study is often quoted as the 
basis for much of the animal and human studies subsequently carried out. The 
hypocholesterolaemic effects of probiotic Lactobacillus and Bifidobacteria strains on mice, rat, 
and human are summarised in Table 1. Taranto et al. [2,3] observed that administration of L. 
reuteri to mice reduced the serum total cholesterol (TC) by 20% and increased the ratio of  
HDL-C  to  LDL-C by  17%. Mice fed L. plantarum PH04 significantly (P<0.05) reduced serum  
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 Probiotic strains       Effects     References 
Mice 
 
L. reuteri 
 
 
 
 
 
 
L. fermentum SM-7 
Serum TC lowered 
 
 
Serum TC lowered 
 
Serum LDL-C lowered 
 
Serum TC and LDL-C lowered 
Taranto et al. (1998, 
2003) 
 
Ngyuen et al. (2007) 
 
Jeun et al. (2010) 
 
Pan et al. (2011) 
 
Rats 
 
A mixture of probiotic 
microorganisms or L. 
acidophilus 
 
 
B. longum SPM1207 
 
 
 
B. longum 
SPM1207(sonication 
killed) 
 
L. plantarum Lp91 
 
 
L. plantarum 9-41-A 
Serum TC lowered 
 
 
 
 
Serum TC and LDL-C lowered
 
 
 
Serum TC and LDL-C lowered
 
 
 
Plasma TC and LDL-C lowered
  
Plasma HDL-C increased 
 
Serum TC and LDLC lowered 
 
Fukushima and 
Nakano (1995, 1996, 
1999) 
 
 
Usman and Hosono 
(2000) 
 
 
Lee et al. (2009) 
 
 
 
Shin et al. (2010) 
 
Kumar et al. (2011) 
 
Xie et al. (2011) 
 
Human 
 
Probiotic-fermented 
milk product 
 
 
 
 
L. acidophilus L1 
 
B. longum BL1 
 
L. acidophilus 
 
 
Serum Total Cholesterol 
Variable data from 1974-1997 
 
Variable data from  
1988-1998 
 
Serum TC lowered 
 
Serum TC lowered 
  
No changes in blood lipid 
parameters 
 
Taylor and Williams 
(1998) 
 
De Roos and Katan 
(2000) 
 
Anderson & 
Gilliland, 1999 
Xiao et al., 2003 
 
Lewis and 
Burmeister (2005) 
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 Probiotic strains       Effects     References 
L. fermentum 
 
 
L. acidophilus and B. 
lactis 
 
L. reuteri NCIMB 30242
No changes in blood lipid 
parameters 
 
Serum TC  
 
 
Serum HDL-C increased 
Serum TC and LDL-C 
Simons et al. (2006) 
 
 
Ataie-Jafari et al 
(2009) 
 
Jones et al. (2012) 
Table 1. Hypocholesterolaemic effects of probiotic Lactobacillus and Bifidobacteria strains in mice, rats 
and humans 
cholesterol by 7% as compared to the control group [4]. The L. plantarum PH04 strain was 
isolated from infant faeces and reported to be able to produce bile salt hydrolase enzyme in 
vitro. In another study, Jeun et al. [5] demonstrated that LDL-C was significantly (P < 0.05) 
lower (by 42%) in mice fed L. plantarum KCTC3928 and fecal bile acid excretion was 
accelerated (45%). They also found expressions of the LDL-receptor and 3-hydroxy-3-
methylglutaryl coenzyme A reductase were marginally affected by feeding L. plantarum 
KCTC3928 but interestingly the gene expression and protein levels of CYP7A1 were 
significantly upregulated [5]. The gene CYP7A1 encodes for cholesterol 7-α-hydroxylase, the 
rate-limiting enzyme in the bile acid biosynthetic pathway in liver and thus controls 
cholesterol and bile acid homeostasis [65]. The increase in cholesterol 7-α-hydroxylase may 
explain the increase in fecal bile excretion and low serum cholesterol level observed by Jeun 
et al [5] since bile acid formation is a major pathway of cholesterol excretion from the body. 
Recently, Pan et al. [6] isolated L. fermentum SM-7 from a fermented milk drink (koumiss) 
and it was found to exhibit acid and bile tolerance and exhibited antimicrobial activity 
against E. coli and S. aureus in vitro. In mice, L. fermentum SM-7 significantly reduced serum 
TC and LDL-C but did not increase HDL-C significantly [6].  The study also showed that 
there was no bacterial translocation in the liver, spleen, or kidney of the treated mice 
indicating safety of the Lactobacillus strain[6].  
In a series of experiments in rats, Fukushima and Nakano [7,8], and Fukushima et al. [9] 
showed that L. acidophilus or a mixture of probiotic microorganisms consistently reduced the 
serum TC. Usman and Hosono [10] also observed a significant reduction in TC and LDL-C 
in rats fed L. gasseri. In a more recent study, B. longum SPM1207 isolated from healthy adult 
Koreans reduced serum TC and LDL-C significantly (p <0.05), and slightly increased serum 
HDL-C in rats [11]. In another study, Shin et al. [10] demonstrated that B.  longum SPM1207, 
although killed by sonication, could significantly reduce serum TC and LDL-C, but with no 
significant improvement in HDL-C when fed to rats for 3 weeks [66].  Kumar et al. [67] 
revealed a 23% reduction in plasma TC, 38% reduction in LDL-C and 19% increase in HDL-
C of rats fed with L. plantarum Lp91, a bile salt hydrolase producing strain. The faecal 
excretion of cholic acid was also found to be significantly higher in the probiotic-fed rats [6].  
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The latest study also consistently showed significant reduction by about 25% and 33% of 
serum TC and LDL-C respectively in rats fed L. fermentum 9-41-A. This strain was also 
isolated from faeces of healthy adults and selected for its probiotic characteristics [6].   
In contrast to animal models, studies in humans conducted between 1974 to 1997 (reviewed 
by Taylor and Williams [14]) and from 1988 to 1998 ( reviewed by de Roos and Katan [15])  
indicate that the role of fermented milk products as hypocholesterolaemic agents was 
equivocal, as the clinical studies performed gave variable results and no firm conclusions 
could be drawn. The contradictory results observed were mainly related to the experimental 
designs especially the use of inadequate sample size and variations in the baseline levels of 
blood lipids [68]. Anderson and Gilliland [16] conducted a randomised, placebo-controlled, 
crossover 10-week study that involved 48 hypercholesterolaemic subjects. The subjects 
consumed milk fermented containing L. acidophilus L1 twice daily. The serum TC of subjects 
who consumed the fermented milk was significantly reduced when compared to those who 
consumed placebo. Xiao et al. [17] used a randomised, single-blind, parallel study for 4 
weeks amongst 32 subjects. Subjects who consumed yoghurt containing B. longum BL1 had 
significantly reduced serum TC and LDL-C as compared to those given placebo yoghurt. 
Lewis and Burmeister [69] however reported that freeze- dried L. acidophilus 
supplementation had no effect on elevated cholesterol subjects using a randomised, placebo-
controlled, crossover 6-week study. Simons et al. [70] in a double blind, placebo-controlled, 
parallel design trial also reported once again no beneficial effects on blood lipids after 
supplementation of L. fermentum for 10 weeks in volunteers with TC of about 4 mmol/L. 
Ataie-Jafari et al. [18] reported that L. acidophilus and B. lactis exhibited cholesterol-lowering 
effect on hypercholesterolemic subjects. They used a placebo controlled, randomised, 
crossover trial for 6 weeks, in healthy subjects with serum TC of 5.17–7.76 mmol/l. The most 
recent study was that conducted by Jones et al. [19] on 114 hypercholesterolaemic adults 
who consumed yoghurt formulated to contain microencapsulated  BSH-active L. reuteri 
NCIMB 30242 twice daily for 6 weeks. This double-blind, placebo-controlled, randomised, 
parallel, multi-centre study showed significant reductions in serum LDL-C (9%), TC (5%) 
and non–HDL-C (6%) over placebo but the serum concentrations of HDL-C remained 
unchanged.  
A meta-analysis based on six studies was conducted by Agerhol-Larsen et al. [72] on the 
hyocholesterolaemic effect of fermented dairy product on plasma cholesterol levels. The 
short term intervention study showed reductions in TC (-8.51 mg/dL) and LDL-C (-7.74 
mg/dL) in subjects who consumed the fermented dairy product when compared to the 
control [72]. Later, Guo et al. [71] conducted another meta-analysis of randomised controlled 
trials that evaluated the effects of probiotics consumption on blood lipids. Their study was 
based on 13 trials of 485 participants with high, borderline high and normal cholesterol 
levels. The results showed that subjects who received probiotics had significantly lower TC 
(-6.40 mg/dL) and LDL-C (-4.90 mg/dL) as compared to those taken placebo. Both the meta 
analyses resulted in a similar observation.  It seems that the hypocholesterolaemic effects of 
probiotics in human clinical trials in the recent years have been more consistent.  
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6. Proposed mechanisms of cholesterol reduction by lactic acid bacteria  
in vitro 
Although studies have shown that some lactic acid bacterial strains have a 
hypocholesterolaemic effect on the host, the mechanism(s) involved is not fully understood. 
Different hypotheses have been advanced to explain the hypocholesterolaemic effect of 
lactic acid bacteria in vitro. There was little or no information on the direct action of cultured 
milk products in reducing cholesterol until Gilliland et al. [24] and Walker and Gilliland [25] 
reported that cholesterol removal in vitro could be due to the active up-take or assimilation 
of cholesterol by the bacterial cell. From then on, the cholesterol assimilation model was 
frequently used to explain the in vivo hypocholesterolaemic effects.  
Based on their findings, Gilliland et al. [24] proposed that the uptake of cholesterol by 
Lactobacillus acidophilus strains occurred only when the cultures were grown in the presence 
of bile under anaerobic conditions. They also found that uptake of cholesterol increased 
with increasing concentrations of bile salts in the media, and the uptake appeared to level 
off at oxgall concentrations greater than 0.4%. Noh et al. [26] noted that cholesterol removed 
from the culture supernatant of L. acidophilus incubated in the presence of bile salt was 
accompanied by an increase in the amount of cholesterol in the cell pellet. Noh et al. [26] 
noticed that cells that were grown in the presence of cholesterol micelles and bile salts were 
more resistant to lysis by sonication, suggesting that assimilation of cholesterol into the 
cellular membrane, resulted in sturdier bacterial cells. This lends support to the idea that cell 
membrane alteration occurred in the presence of both bile salts and cholesterol. They also 
observed that assimilation occurred both at pH 6.0 and without pH control. Similar results 
have been reported for bifidobacteria [73] and lactococci [28]. Kimoto et al. [28] observed 
that both live and heat-killed Lactococcus lactis subsp. lactis biovar diacetylactis N7 were able 
to remove cholesterol from growth media. However, the amount of cholesterol removed by 
live cells was significantly higher than that removed by dead cells. They found that cell 
density and dry weight were higher when the cells were grown in the presence of 
cholesterol, and the rate of cholesterol removal was more rapid during their exponential 
growth phase. Since only living cells can possibly uptake cholesterol into their membranes, 
they concluded that the mechanisms of cholesterol removal by the live strain were due to 
cholesterol assimilation and binding, while removal of cholesterol by dead cells was only 
due to binding onto bacterial cell surface. They also observed a difference in the fatty acid 
distribution pattern for Lactococcus grown with or without cholesterol. Later Taranto et al. 
[74] reported modifications in the lipid profile of L. reuteri grown with cholesterol, while 
Liong and Shah [75] also observed alteration in the fatty acid profiles of lactobacilli grown in 
the presence of cholesterol in the growth medium.  Pigeon et al. [29] suggested that 
cholesterol removal by L. delbrueckii and Streptococcus thermophilus strains were due to 
binding of free bile acids to their cell membranes through exocellular polysaccharide (EPS). 
They found that the strains, which produced the most EPS, bound the greatest amount of 
bile acids, while the strains that produced the least amount of EPS only bound minimal 
amounts of bile acids and conjugated bile acids did not bind to the EPS. They hypothesized 
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that the strains reduced serum cholesterol levels by binding to enhance excretion of free bile 
acids via the faeces. Tol and Aslim [76] also demonstrated a correlation between cholesterol 
removal and EPS production of L. delbrueckii spp. 
However, Klaver and Van der Meer [23] proposed another mechanism of cholesterol 
reduction by lactic acid bacteria. They pointed out that the experimental set up to prove the 
cholesterol assimilation  as hypothesized by Gilliland et al. [24] and Walker and Gilliland 
[25] did not take into   account the effects  of bacterial  deconjugation of  bile salts. They 
suggested that the removal of cholesterol was due to the disruption of the cholesterol 
micelles caused by bile salt deconjugation and co-precipitation of cholesterol with free bile 
salts as the pH of the medium dropped because of acid production during growth of 
lactobacilli and bifidobacteria. This conclusion was based largely on their observation that 
no cholesterol was removed when the growth medium was maintained at pH 6.0, a pH at 
which free bile acids would remain in solution and prevent the precipitation of free bile 
salts. They associated these results to the decreased solubility of free bile acids under acidic 
conditions which in turn reduced the solubility of cholesterol (thus termed co-precipitation 
of cholesterol). Taranto et al. [77] and Ahn et al. [21] also stressed that removal of cholesterol 
was closely related to bile salt deconjugation at low pH. Brashears et al. [27] demonstrated 
that strains of L. acidophilus were able to deconjugate bile salts and remove cholesterol when 
grown at both pH 6.0 and without pH control. On the other hand, strains of L. casei grown at 
pH 6.0 removed very little cholesterol compared to the same strains grown at uncontrolled 
pH. However, examination of cellular membranes of L. casei grown under both conditions 
revealed no cholesterol deposits. Therefore, the authors concluded that removal of 
cholesterol by L.  casei was most likely due to co-precipitation of cholesterol with 
deconjugated bile salts at pH less than 6.0, while removal of cholesterol by L. acidophilus was 
due to assimilation of cholesterol into cellular membranes. Cholesterol reduction may be 
strain specific. 
In an attempt to determine the validity of the hypothesis of assimilation and/or precipitation 
of cholesterol by Lactobacillus and Bifidobacterium species, Grill et al. [78] cultured a strain of 
each species in a medium containing different bile salts. They found that the cholesterol 
removing ability of bifidobacteria varied according to the type of bile salts. In the presence 
of taurocholic acid, the removal of cholesterol was due to bacterial uptake and co-
precipitation, but in the presence of oxgall, only co-precipitation was observed. It seems that 
the composition of bile salt is another important factor in determining the amount of 
cholesterol removed through co-precipitation. Many studies, hypothesised that lactic acid 
bacterial strains are able to remove cholesterol through  a combination of two or more 
mechanisms which includes, assimilation of cholesterol during growth, binding of 
cholesterol to cellular membrane and deconjugation of bile salts [27,75,79-86 ].   
More recently, another mechanism was hypothesized by Kim et al. [30] who found the cell-
free supernatant of L. acidophilus ATCC 43121 to contain proteins that were able to 
significantly reduce cholesterol levels even after heat-treated or controlled at pH 6.0. The 
extract exhibited greatest cholesterol-reducing activity when maintained at pH 4.0. 
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Subsequent analysis identified the up-regulated proteins to be associated with stress 
response, translation, and metabolic processes and also have functions related to the cell 
membranes. Huang and Zheng [87] reported that soluble factors produced by L. acidophilus 
have the ability to inhibit cholesterol absorption in Caco-2 cells by down-regulating the gene 
expression of Niemann-Pick C1-like 1 (NPC1L1). NCPC1L1 protein has been identified as a 
key player in cholesterol absorpstion and a promising target for cholesterol–lowering 
mechanisms [88]. These studies suggest the possibility to alter gut microbiota through 
supplementation of probiotics for reduction of cholesterol absorption. Lee et al. [89] 
investigated cholesterol reducing activity of lactobacilli using genetic and proteomic 
analysis and reported that ccpA which encodes the catabolite control protein to play an 
important role in cholesterol reducing activity of probiotics. They also hypothesized that 
membrane associated proteins play an important role in probiotic cholesterol reduction.   
7. Cholesterol reduction by lactic acid bacteria in vivo 
It has been suggested that assimilation of cholesterol during growth of probiotic lactic acid 
bacteria and binding of cholesterol to their cellular membrane would result in less 
cholesterol available for absorption, leading to reduced serum cholesterol of the host [24]. 
Fukushima and Nakano [7] suggested that the hypocholesterolaemic effects could also be 
due to the ability of probiotic organisms to inhibit hydroxymethylglutaryl coenzyme A 
(HMG CoA) reductase. It is well documented that suppression of HMG CoA reductase is 
correlated with the inhibition of cholesterol synthesis. Short chain fatty acids (SCFA) have 
also been implicated to be involved in the reduction of cholesterol. Hara et al. [90] observed 
that a dietary SCFA mixture and SCFA produced by the fermentation of sugar beet fibre 
significantly reduced plasma cholesterol levels in rats. They suggested that absorbed SCFA 
might have suppressed the cholesterol synthesis rate in the liver and were involved in the 
cholesterol-lowering effect.  Fukushima et al. [9] also suggested that the lowering of 
cholesterol level in rats fed probiotics was probably due to specific SCFA metabolites such 
as propionic acid and butyric acid. Propionate and butyrate are able to reduce hepatic 
cholesterol synthesis [91]. However, researchers acknowledge that deconjugation of bile 
salts by probiotic strains could be an important factor in lowering serum cholesterol through 
interference with the enterohepatic absorption of bile salts and cholesterol.  
8. Enterohepatic circulation of bile acids 
Bile acids are synthesised from cholesterol in the liver and stored in the gall bladder. The 
steroid is conjugated with an amide bond at the carboxyl C24 position to one of two amino 
acids, glycine and taurine [92], before it is excreted into the small intestine. The conjugated 
bile salts are amphipathic in nature and form micelles that facilitate digestion, emulsification 
and absorption of lipids from the small intestine [93]. The conjugated bile salts are readily 
absorbed in the gastrointestinal tract by active transport mechanisms and are returned to the 
liver; this process is known as enterohepatic circulation. A large pool of bile acids 
accumulates and undergoes a number of enterohepatic cycles daily [94].  
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The conversion of cholesterol to bile acids is the major route by which cholesterol is 
metabolized. To date, only two studies have shown the ability of probiotics strains [5,95] to 
be able to up-regulate CYP7A1 an enzyme that catalyzes the conversion of cholesterol to bile 
acids. An increase in CYP7A1 leads to reduction in hepatic cholesterol levels [5,95] and 
increase fecal cholesterol [95] and bile acids [5] excretion in hamsters and mice respectively. 
However, in the intestine, the bile salts may also be deconjugated by probiotics strains 
through bile salt hydrolase activity resulting in free bile salts. Free bile salts are more likely 
to be excreted via the faeces than the conjugated ones [96-98].  
9. Significance of bile salt deconjugation by probiotic strains 
The peptide-like bond between the bile acid and taurine or glycine is not cleaved by most 
proteolytic enzymes, but it is by bile salt hydrolase (BSH), an intracellular enzyme [99]. 
Deconjugation of bile salts in vitro, has been demonstrated by intestinal bacteria, such as 
Clostridium [100], Lactobacillus [101], Streptococcus [101], and Bifidobacterium [100]. The BSH 
enzyme catalyses the hydrolysis of conjugated bile acid to produce free bile salt and the 
corresponding amino acid. The biological function of BSH in these microorganisms remains 
unclear. However, in recent years, BSH has received attention because of its potential 
therapeutic benefits for reducing cholesterol. Upon hydrolysis, the physico-chemical 
properties of bile salts change drastically.  Deconjugated bile acids are less soluble at low pH 
and less absorbed in the intestine and are more likely to be excreted in the faeces [102]. 
Excretion of free bile acids via the faeces is the primary route of elimination of cholesterol 
from humans and other animals [5]. To maintain bile salt homeostasis, more bile acids need 
to be synthesised and this in turn will reduce cholesterol in the body pool as cholesterol is 
the precursor for bile acids. The hypocholesterolaemic effect of lactic acid bacteria in this 
manner is comparable with that of cholestyramine treatment, which like other bile salt 
sequestrants, binds bile salts and prevents them from being reabsorbed [97]. Intestinal 
microflora plays a major role in interfering with the reabsorption of bile acid from the 
intestine, thus, promoting their excretion [97]. Increased faecal bile acid concentrations have 
also been observed in probiotic-fed mice [5,10], rats [7,67] and in human [19]. These studies 
strongly suggest that the deconjugating activity of BSH-active lactic acid bacteria may be 
associated with the hypocholesterolaemic effect.  
The significance of BSH activity other than its hypocholesterolaemic effect, is far from 
understood. However, it has been suggested that certain BSH-active bacteria are able to 
utilise the amino portion of the deconjugated bile salt. Van Eldere et al. [103] reported that 
bacteria that are able to produce BSH may be able to use the amino acid, taurine, as an 
electron acceptor which can improve growth. De Smet et al. [97] suggested that 
deconjugation may be a detoxification mechanism which is of vital importance to the 
Lactobacillus cell. It has also been suggested that BSH is a detergent shock protein that 
protects the bacteria from the toxicity of bile acids in the gastrointestinal tract [104]. Moser 
and Savage [105] reported that BSH activity may be important for the bacteria to survive 
and colonise the gastrointestinal tract. Given the potential importance of the enzyme, genes 
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encoding it may be important targets for genetic manipulation. Although lactobacilli are 
able to deconjugate bile salts to unconjugated primary bile acids, they do not further 
transform the unconjugated bile acids into deoxycholate (secondary bile acids) [21]. This is a 
good probiotic trait because formation of secondary bile acids, which are usually produced 
by intestinal bacteria, may contribute to colon cancer and gallstones. Ooi and Liong [106] 
reported that there has been no study that specifically evaluated the detrimental effects of 
BSH of probiotics in humans and that further studies are required.  
10. Conclusion 
The consumption of probiotics is gaining popularity especially in the maintenance of health 
and prevention of disease. In particular, the role of probiotics as a hypocholesterolaemic 
agent has been explored extensively. Progress has been made in the recent years on the 
selection, identification and characterization of strains that actually fulfill the criteria of true 
probiotic microorganisms and that are able to exert cholesterol reducing effects in vitro. 
However, much remains to be done on the mechanism of action as it has not been very well 
understood. The potential of probiotics in reducing cholesterol levels in animal models have 
been quite consistent in the recent years but but larger and better controlled human trials 
with scientifically substantiated evidence of the benefits are required.  
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